MIdWestOne Financial Group Inc. Has $5.22 Million Stock Position in United Therapeutics Corporation $UTHR

MIdWestOne Financial Group Inc. raised its position in United Therapeutics Corporation (NASDAQ:UTHR) by 13.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,704 shares of the biotechnology company’s stock after acquiring an additional 1,258 shares during the period. MIdWestOne Financial Group Inc.’s holdings in United Therapeutics were worth $5,216,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in UTHR. Clearstead Advisors LLC boosted its holdings in shares of United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 23 shares during the period. Independent Advisor Alliance boosted its holdings in shares of United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 27 shares during the period. Bessemer Group Inc. boosted its holdings in shares of United Therapeutics by 2.6% during the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after acquiring an additional 28 shares during the period. Florida Financial Advisors LLC boosted its holdings in shares of United Therapeutics by 5.4% during the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after acquiring an additional 28 shares during the period. Finally, Signaturefd LLC boosted its holdings in shares of United Therapeutics by 4.1% during the fourth quarter. Signaturefd LLC now owns 896 shares of the biotechnology company’s stock worth $437,000 after acquiring an additional 35 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Up 0.2%

Shares of UTHR stock opened at $545.40 on Friday. The stock has a market cap of $23.15 billion, a P/E ratio of 20.13, a price-to-earnings-growth ratio of 1.77 and a beta of 0.57. The stock has a 50 day simple moving average of $567.24 and a 200 day simple moving average of $521.17. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the firm posted $6.63 earnings per share. Analysts forecast that United Therapeutics Corporation will post 26.84 EPS for the current year.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $547.07, for a total value of $4,540,681.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $24,712,246.04. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $547.50, for a total value of $5,475,000.00. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,334,610. This trade represents a 34.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 624,984 shares of company stock worth $352,682,302. Company insiders own 8.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Morgan Stanley set a $516.00 price objective on United Therapeutics in a report on Thursday, May 7th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Royal Bank Of Canada reduced their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. UBS Group boosted their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, HC Wainwright boosted their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.